FMP

FMP

Enter

IMCR - Immunocore Holdings ...

Financial Summary of Immunocore Holdings plc(IMCR), Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of imm

photo-url-https://financialmodelingprep.com/image-stock/IMCR.png

Immunocore Holdings plc

IMCR

NASDAQ

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

40.53 USD

-0.57 (-1.41%)

About

ceo

Dr. Bahija Jallal Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.immunocore.com

exchange

NASDAQ

Description

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma,...

CIK

0001671927

ISIN

US45258D1054

CUSIP

45258D105

Address

92 Park Drive

Phone

44 12 3543 8600

Country

GB

Employee

497

IPO Date

Feb 5, 2021

Summary

CIK

0001671927

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

45258D105

ISIN

US45258D1054

Country

GB

Price

40.53

Beta

0.83

Volume Avg.

710.11k

Market Cap

2.03B

Shares

-

52-Week

38.78-76.98

DCF

-0.34

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-25.65

P/B

-

Website

https://www.immunocore.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest IMCR News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep